EHA 2020 | Assessing high-risk AML

Name: Assessing high-risk AML
Uploaded: 2020-06-15T00:00:00Z
Duration: 3 min 51 s
Description: Nigel Russell, MD, of Guy's Hospital NHS Trust, London, UK, explores how high-risk acute myeloid leukemia (AML) can be identified as well as the importance of genomic profiling and minimal residual disease (MRD) in AML assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Nigel Russell • 15 Jun 2020

EHA 2020

Acute Myeloid Leukemia Leukemia

Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, explores how high-risk acute myeloid leukemia (AML) can be identified as well as the importance of genomic profiling and minimal residual disease (MRD) in AML assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).